Verastem

Press Releases

July 27, 2021
Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021
July 19, 2021
Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt
July 6, 2021
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 24, 2021
Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors
May 25, 2021
Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference
May 24, 2021
Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
May 11, 2021
Verastem Oncology Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
March 18, 2021
Verastem Oncology Reports Fourth Quarter and Full Year 2020 Financial Results, Clinical Updates and Guidance for Key Milestones in 2021 and 1H 2022
March 2, 2021
Verastem Oncology to Participate in the H.C. Wainwright Global Life Sciences Conference
January 20, 2021
Frank Neumann, M.D., Ph.D., to Depart Verastem Oncology
January 7, 2021
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 6, 2021
Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
January 5, 2021
Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference

E-mail Alerts

You may automatically receive Verastem Oncology financial information by e-mail. To choose your options for e-mail notification, please enter your e-mail address below and click Submit.

Investor Contact

getty
Ajay Munshi

Investor Relations
781.469.1579
info@verastem.com

Sherri Spear

Argot Partners
617.533.0020
sherri@argotpartners.com

Investor Kit